Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: A systematic review and meta-analysis
- 31 December 2006
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 118 (3), 321-333
- https://doi.org/10.1016/j.thromres.2005.08.007
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trialThe Lancet, 2003
- ABC of antithrombotic therapy: Antithrombotic therapy for atrial fibrillationBMJ, 2002
- Ethnic Differences in Patient Perceptions of Atrial Fibrillation and Anticoagulation TherapyStroke, 2002
- Optimal Intensity of Warfarin Therapy for Secondary Prevention of Stroke in Patients with Nonvalvular Atrial FibrillationStroke, 2000
- Alternate-day dosing of aspirin in atrial fibrillationAmerican Heart Journal, 1999
- Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillationThe American Journal of Cardiology, 1998
- Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trialsJAMA, 1995
- Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boardsJAMA, 1992
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986
- Bias in Treatment Assignment in Controlled Clinical TrialsNew England Journal of Medicine, 1983